News: Allergan Inc (AGN)

AGN on New York Consolidated

224.17USD
23 Jan 2015
Change (% chg)

$1.38 (+0.62%)
Prev Close
$222.79
Open
$222.37
Day's High
$224.28
Day's Low
$222.29
Volume
2,081,737
Avg. Vol
2,915,323
52-wk High
$224.28
52-wk Low
$110.62

Search Stocks
Select another date:

Thu, Jan 15 2015

Photo

Actavis aims to add Allergan CEO to its board: sources

SAN FRANCISCO - Allergan Inc Chief Executive David Pyott is close to joining the board of directors of Actavis Plc , which reached a deal to buy the Botox-maker for $66 billion in November, three people familiar with the matter said on Thursday.

Ackman's Pershing Square sees big payoff from Allergan deal

BOSTON - Hedge fund mogul William Ackman told investors they could see a $6 billion payday when he closes the chapter on Allergan Inc., his firm's biggest bet of 2014.

UPDATE 1-Ackman's Pershing Square sees big payoff from Allergan deal

(Adds details from Ackman's letter about other investments)

Ackman's Pershing Square still holds 26.6 million Allergan shares

BOSTON, Nov 26 - Hedge fund manager William Ackman told investors in a letter that his firm still owns 26.6 million shares in Allergan Inc. which were valued at $5.6 billion one week after the Botox maker agreed to sell itself to rival pharmaceutical company Actavis Plc.

Actavis mulls job cuts, China expansion: Bloomberg

- Generic drugmaker Actavis Plc is planning to cut employees and expand in China, a Bloomberg report said citing an interview by Chief Executive Officer Brent Saunders on Bloomberg Television.

A

CORRECTED-BRIEF-Valeant Pharma reports 0.1 percent stake in Allergan

(Corrects first bullet point to remove incorrect reference to Valeant's prior stake in Allergan)

Valeant slashes stake in Allergan after losing bid

- (Refiles Nov. 20 story to correct reference to previous stake)

CORRECTED-Valeant slashes stake in Allergan after losing bid

Nov 20 - Valeant Pharmaceuticals International Inc said it cut its stake in Allergan Inc to 0.1 percent, three days after Actavis Plc trumped its offer for the Botox maker.

Suvretta's Cowen says Actavis stock could nearly double

NEW YORK - After months of fending off a hostile bid, Allergan Inc Chief Executive David Pyott made the right call in selling to rival Actavis Plc , whose stock price could nearly double in the next two years, a prominent investor said on Wednesday.

Select another date:

Press Releases

Search Stocks